GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioceltix SA (WAR:BCX) » Definitions » Minority Interest

Bioceltix (WAR:BCX) Minority Interest : zł0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bioceltix Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Bioceltix's minority interest for the quarter that ended in Sep. 2024 was zł0.00 Mil.


Bioceltix Minority Interest Historical Data

The historical data trend for Bioceltix's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioceltix Minority Interest Chart

Bioceltix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Minority Interest
- - - - -

Bioceltix Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bioceltix Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Bioceltix Business Description

Traded in Other Exchanges
Address
Bierutowska 57-59 Street, Wroclaw, POL, 51-317
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.